<DOC>
	<DOCNO>NCT00003622</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness vinorelbine plus paclitaxel treating patient metastatic prostate cancer refractory hormone therapy .</brief_summary>
	<brief_title>Vinorelbine Plus Paclitaxel Treating Patients With Metastatic Prostate Cancer That Is Refractory Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine clinical benefit response ( include improvement quality life ) vinorelbine paclitaxel patient metastatic hormone-refractory prostate cancer . II . Correlate PSA response clinical benefit response patient . III . Determine objective response rate duration remission patient measurable disease treat regimen . IV . Further assess toxicity combination cohort prostate cancer patient . V. Examine survival characteristic patient undergo regimen . OUTLINE : This open label study . Patients receive vinorelbine IV 6-10 minute day 1 , 2 , 3 paclitaxel IV 3 hour day 3 follow vinorelbine . Course repeat every 28 day absence disease progression unacceptable toxicity . Quality life assess treatment course . Patients follow death . PROJECTED ACCRUAL : A total 30 patient accrue study 15-30 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic adenocarcinoma prostate hormone refractory Hormonerefractory define least 50 % increase PSA continue hormonal therapy Must receive prior hormonal manipulation include either orchiectomy LHRH agonist Must symptomatic stable dose pain medication No document CNS involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 12 Life expectancy : At least 16 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.8 mg/dL Renal : Creatinine great 1.8 mg/dL Other : Not HIV positive No concurrent infection No concurrent medical psychiatric illness precludes study compliance No prior concurrent second malignancy past 5 year except basal squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : See Disease Characteristics At least 4 week since prior antiandrogens If patient receive prior antiandrogens , PSA level reassess 4 week interval decrease PSA level registration study Radiotherapy : Prior radiotherapy allow Must recover prior radiotherapy Concurrent radiotherapy symptomatic bone lesion allow Surgery : Not specify Other : No concurrent therapeutic study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>